{"id":"NCT01290679","sponsor":"Janssen R&D Ireland","briefTitle":"An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants","officialTitle":"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of TMC435 Versus Placebo as Part of a Treatment Regimen Including Peginterferon α-2a (Pegasys®) and Ribavirin (Copegus®) or Peginterferon α-2b (PegIntron®) and Ribavirin (Rebetol®) in Treatment-naïve, Genotype 1, Hepatitis C-infected Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03","primaryCompletion":"2013-02","completion":"2013-02","firstPosted":"2011-02-07","resultsPosted":"2014-06-13","lastUpdate":"2014-06-13"},"enrollment":393,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"TMC435","otherNames":[]},{"type":"DRUG","name":"Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b)","otherNames":["PegIFNα-2a (Pegasys)","PegIFNα-2b (PegIntron)"]},{"type":"DRUG","name":"Ribavirin (RBV)","otherNames":["Copegus","Rebetol"]}],"arms":[{"label":"TMC435","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to investigate the effectiveness and safety of TMC435 compared with placebo in participants who are infected with genotype 1 hepatitis C virus who have never received treatment before. Participants will also receive peginterferon alfa-2a or peginterferon alfa-2b and ribavirin as part of their treatment.","primaryOutcome":{"measure":"The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)","timeFrame":"Week 36 or Week 60","effectByArm":[{"arm":"TMC435 150mg 12Wks PR24/48","deltaMin":81.3,"sd":null},{"arm":"PBO 12Wks PR48","deltaMin":50,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":60,"countries":["United States","Argentina","Austria","Belgium","Brazil","Bulgaria","France","Germany","Netherlands","Poland","Portugal","Puerto Rico","Slovakia","Spain","Turkey (Türkiye)"]},"refs":{"pmids":["25445400","24907224"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":257},"commonTop":["Fatigue","Headache","Pyrexia","Influenza like illness","Pruritus"]}}